The FDA issued approval for Antares Pharma‘s (Ewing, New Jersey) needle-free injection device for use with Tev-Tropin brand human growth hormone (hGH) from Teva out of Petach Tikva, Israel. The device will be marketed under the name Tev-Tropin Tjet Injector system.
From the injector info page:
Reusable Needle-Free Injectors (Medi-Jector VISION®) deliver precise medication doses through high-speed, pressurized liquid penetration of the skin without a needle. These reusable, variable-dose devices are engineered to last for a minimum of two years and are designed for easy use, facilitating self-injection with a disposable plastic needle-free syringe to assure safety and efficacy. The associated disposable plastic needle-free syringe, offers high precision liquid medication delivery through an opening that is approximately half the diameter of a standard, 30-gauge needle and it is designed to last for approximately one week. Antares has sold the Medi-Jector VISION® for use in more than 30 countries to deliver either insulin or human growth hormone (“hGH”).
Press release: Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin® (Human Growth Hormone)
Product pages: Tev-Tropin; Antares Pharma injection devices…
The Guardia Pro Protective Embryo Transfer Catheter makes cervical flushing or aspiration unnecessary prior to embryo placement.
From the announcement by Medtronic:
Researchers from EnGeneIC, an Australian firm from the suburbs of Sydney, have developed a cancer treatment that so far performed remarkably well in animal tests. By encompassing toxins in “minicells”, made off of chunks of bacteria cell membrane harvested during division, they were able to deliver chemicals precisely to neoplasm sites while helping bypass the tumor’s natural defenses.
